Table of Contents
mRNA Market Overview
mRNA, or messenger RNA, is essential for protein synthesis in cells. It transcribes genetic information from DNA in the nucleus and carries it to ribosomes in the cytoplasm through a process called transcription, facilitated by RNA polymerase.
Eukaryotic cells modify mRNA by adding a 5′ cap a poly-A tail and removing non-coding sequences (introns) via splicing.
Processed mRNA then moves to ribosomes, where it translates codons into amino acids, forming proteins. After translation, mRNA is typically broken down, controlling protein levels.
mRNA technology has recently advanced in vaccine development, such as in COVID-19 vaccines. Where mRNA prompts cells to produce viral spike proteins, stimulating immune responses.
Market Drivers
The global mRNA market is driven by significant factors that are shaping its rapid growth. Advances in mRNA technology particularly demonstrated through successful COVID-19 vaccines. They have propelled its application in therapeutics for diseases like cancer and genetic disorders.
The demand for personalized medicine is also boosting adoption, as mRNA allows tailored treatments based on genetic profiles.
Increased investment from the public and private sectors supports ongoing research and development. Focusing on enhancing mRNA synthesis, delivery, and stability.
Regulatory approvals and partnerships across pharmaceutical and biotech sectors further accelerate market expansion. Ensuring broader commercialization and accessibility of mRNA-based therapies worldwide.
Market Size
The global market for mRNA vaccines and therapies is projected to grow significantly. Reaching approximately $68 billion by 2030 from an estimated $27 billion in 2020. This indicates a compound annual growth rate of nearly nine percent over the decade.
RNA analysis market size was valued at USD 9.58 billion and is expected to reach USD 34.37 billion in 2032
List of Major Companies
These are the top ten companies operating in the mRNA Market:
- Abbott
- Merck
- Sanofi
- Thermo-Fisher-Scientific
- Bristol-Myers-Squibb
- Teva
- Roche
- Pfizer
- Qiagen
- GE-Healthcare
Abbott
Company Overview
| Establishment Year | 1888 |
| Headquarter | Green Oaks, Illinois, U.S. |
| Key Management | Robert B. Ford (Chairman & CEO) |
| Revenue (US$ Bn) | $ 40.1 Billion (2023) |
| Headcount | ~ 114,000 (2023) |
| Website | http://abbott.com/ |
About Abbott Laboratories
Abbott Laboratories is advancing in the mRNA sector and utilizing this technology for healthcare innovations.
Recent milestones include FDA approval of its lab automation system in December 2023 and integrating the FreeStyle Libre 2 Plus sensor with Tandem Diabetes Care’s t insulin pump in January 2024.
These developments underscore Abbott’s commitment to enhancing diagnostic and therapeutic capabilities.
Strategic acquisitions, like Cardiovascular Systems, Inc., further strengthen its portfolio. Abbott continues to perform well in medical devices and nutrition. With strong growth in products such as Ensure and FreeStyle Libre.
Financially, Abbott reported an 11.6% organic sales increase in 2023. Excluding COVID-19 testing revenue, and forecasts 8-10% organic sales growth for 2024.
Geographical Presence
Abbott Laboratories, headquartered in the United States. It maintains a global presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East/Africa regions.
In North America, Abbott operates extensively in the United States and Canada. In Europe, key markets include Germany, France, the UK, and Italy.
In the Asia-Pacific region, Abbott focuses on China, Japan, India, and Australia. Latin America is prominently featured with operations in Brazil, Mexico, Argentina, and Chile.
Additionally, Abbott has established a foothold in the Middle East and Africa. Including countries like Saudi Arabia, South Africa, and the UAE.
This widespread network supports Abbott’s mission to provide healthcare solutions globally. Ensuring broad access to its diverse portfolio of pharmaceuticals, medical devices, and nutritional products.
Recent Developments
- In June 2024, Abbott Laboratories partnered with the National Association of Community Health Centers to improve access to nutritious food and promote overall health through its Innovation Incubator program.
- In May 2024, Abbott launched a GLP systems Track automation solution.
Merck
Company Overview
| Establishment Year | 1891 |
| Headquarter | Rahway, New Jersey, U.S. |
| Key Management | Robert M. Davis (Chairman, President and CEO) |
| Revenue (US$ Bn) | $ 60.1 B (2023) |
| Headcount | ~ 72,000 (2023) |
| Website | http://merck.com/ |
About Merck
Merck & Co., Inc. is significantly advancing in the mRNA sector through strategic partnerships and innovative product development.
One highlight is its collaboration with Moderna to create personalized cancer vaccines like mRNA-4157/V940. Currently combined with Keytruda for melanoma and now being tested for lung cancer.
Merck is expanding its mRNA capabilities through acquisitions and investments, including co-developing Moderna’s mRNA cancer vaccines.
Clinical trials are assessing these treatments across different cancer types, underscoring Merck’s dedication to leveraging mRNA for groundbreaking cancer therapies.
Geographical Presence
Merck & Co., Inc., globally recognized as Merck Sharp & Dohme (MSD), maintains a strong presence across major regions.
Headquartered in Kenilworth, New Jersey, USA, Merck operates research and manufacturing facilities throughout North America, including Canada.
In Europe, key operations are located in Germany, the UK, and Switzerland, focusing on biopharmaceutical manufacturing.
In the Asia-Pacific region, Merck has established itself prominently in Japan, China, and India through research, manufacturing, and sales activities.
Latin America sees strategic operations in Brazil and Mexico for sales and distribution. Additionally, Merck maintains a significant presence in South Africa and the UAE, emphasizing its global leadership and regional market strategies.
Recent Developments
- In March 2024, Merck acquired Harpoon Therapeutics, Inc., making it a wholly-owned subsidiary.
- In October 2022, Merck exercised its option to co-develop and commercialize the personalized cancer vaccine mRNA-4157/V940 as per their existing Collaboration and License Agreement.
Sanofi
Company Overview
| Establishment Year | 1973 |
| Headquarter | Paris, France |
| Key Management | Paul Hudson (CEO) |
| Revenue (US$ Bn) | $ 50.2 Billion (2022) |
| Headcount | ~ 86,088 (2023) |
| Website | http://sanofi.com/ |
About Sanofi
Sanofi S.A. is expanding its presence in the mRNA sector through strategic acquisitions and substantial investments in research and development.
A pivotal move was the $3.2 billion acquisition of Translate Bio. Which integrated mRNA technology for vaccines and therapeutics into Sanofi’s portfolio.
This acquisition is part of Sanofi’s broader strategy to strengthen its mRNA capabilities. It includes a $1 billion investment to establish an mRNA Center of Excellence in France. Focused on pioneering new mRNA-based vaccines and therapies.
Recent developments include acquiring Origimm Biotechnology to develop an mRNA-based acne vaccine and purchasing Tidal Therapeutics for $160 million to harness mRNA in reprogramming T cells for cancer treatment.
These initiatives underscore Sanofi’s dedication to advancing mRNA technology to meet healthcare needs and expand its innovative pipeline.
Geographical Presence
Sanofi S.A., based in Paris, France, has a strong global presence spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East/Africa.
In North America, it operates R&D and manufacturing facilities while maintaining extensive operations in key European countries such as Germany, the UK, and France.
Across Asia-Pacific, including China and Japan, Sanofi addresses diverse healthcare needs through local manufacturing and research.
In Latin America, it is active in Brazil, Mexico, and Argentina, bolstering regional healthcare access. In the Middle East/Africa, Sanofi supports health initiatives in countries like Saudi Arabia and South Africa.
With a footprint in over 170 countries worldwide, Sanofi continues to innovate and meet local healthcare demands while meeting stringent regulatory requirements.
Recent Development
- In December 2021, Sanofi acquired Origimm Biotechnology to obtain a therapeutic acne vaccine, integrating it with cutting-edge technology.
- In April 2021, Sanofi spent $160 million upfront to purchase a preclinical biotech using mRNA for immune cell reprogramming in humans.
Thermo-Fisher-Scientific
Company Overview
| Establishment Year | 1958 |
| Headquarter | Waltham, Massachusetts, U.S. |
| Key Management | Marc N. Casper (CEO) |
| Revenue (US$ Bn) | $ 42.8 Billion (2023) |
| Headcount | ~ 122,000 (2023) |
| Website | http://www.thermofisher.com/ |
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is deeply involved in the mRNA sector, offering comprehensive solutions from gene synthesis to commercial manufacturing for vaccines and therapeutics.
The company’s portfolio supports mRNA technology development, highlighted by a strategic partnership with Moderna to scale COVID-19 vaccine production.
Recent efforts include strategic acquisitions and partnerships aimed at advancing mRNA capabilities. In early 2024, Thermo Fisher reported robust revenues of $10.34 billion, underscoring strong demand in life sciences.
With expanding capabilities in mRNA manufacturing, Thermo Fisher continues to play a pivotal role in shaping the future of mRNA technologies.
Geographical Presence
Thermo Fisher Scientific Inc. has a robust global presence and is headquartered in Waltham, Massachusetts.
It operates extensively in North America, Europe (including Germany, the UK, and France), and Asia-Pacific (with a focus on China, Japan, and India).
In Latin America, it serves markets in Brazil and Argentina, supporting sectors from healthcare to agriculture.
While its footprint in the Middle East and Africa is more limited, Thermo Fisher maintains operations in key economic hubs, emphasizing its commitment to delivering advanced scientific solutions worldwide.
Recent Development
- In June 2024, Thermo Fisher Scientific Inc. launched a new ultra-cold facility in the EU, bolstering its clinical trial capabilities to expedite advanced therapy development throughout Europe.
- In December 2022, Moderna and Thermo Fisher Scientific entered a 15-year strategic collaboration to facilitate extensive manufacturing in the U.S. of Spikevax®, Moderna’s COVID-19 vaccine, and other upcoming mRNA therapies.
Bristol-Myers-Squibb
Company Overview
| Establishment Year | 1887 |
| Headquarter | Princeton, New Jersey, U.S. |
| Key Management | Chris Boerner (CEO) |
| Revenue (US$ Bn) | $ 45.01 B (2023) |
| Headcount | ~ 34,100 (2023) |
| Website | http://bms.com/ |
About Bristol Myers Squibb
Bristol Myers Squibb (BMS) is actively advancing mRNA technology to innovate oncology treatments. Recently, BMS achieved milestones with the approval of Breyanzi (lisocabtagene maraleucel) for mantle cell lymphoma and ongoing clinical trials for other mRNA therapies.
BMS’s updates include FDA acceptance of supplemental Biologics License Applications (sBLAs) for Opdivo (nivolumab) in combination therapies for various cancers and the European Medicines Agency’s validation of marketing applications for new mRNA treatments such as Krazati (adagrasib) and repotrectinib.
These developments underscore BMS’s commitment to enhancing oncology treatments and bringing effective therapies to patients through mRNA innovations.
Geographical Presence
Founded in the US in 1887, Bristol Myers Squibb (BMS) has grown into a major global biopharmaceutical headquartered in New York City.
BMS operates extensively in North America, with facilities in the US and Canada. In Europe, it maintains a robust presence in key markets like the UK, Germany, and France, supported by research and manufacturing facilities.
In Asia-Pacific, including Japan, China, and Australia, BMS meets diverse healthcare needs. In Latin America, BMS is active in Brazil, Mexico, and Argentina, enhancing healthcare access.
In the Middle East and Africa, BMS collaborates through strategic partnerships to advance healthcare innovations in oncology, immunology, cardiovascular, and hematology, underscoring its global biopharmaceutical leadership.
Recent Developments
- In May 2024, Bristol Myers Squibb received FDA approval for Breyanzi to treat relapsed or refractory mantle cell lymphoma.
- In March 2024, Bristol Myers Squibb’s Opdivo® (nivolumab), combined with cisplatin and gemcitabine, received FDA approval as a first-line treatment for adults with unresectable or metastatic urothelial carcinoma (UC), the most common type of bladder cancer.
Teva
Company Overview
| Establishment Year | 1901 |
| Headquarter | Tel Aviv, Israel |
| Key Management | Richard Francis (President and CEO) |
| Revenue (US$ Bn) | $ 15.8 Billion (2023) |
| Headcount | ~ 35,000 (2023) |
| Website | http://www.tevapharm.com/ |
About Teva Pharmaceuticals
Teva Pharmaceuticals is progressing in the mRNA sector, focusing on innovative therapeutic applications. Recent successes with products like AUSTEDO and AJOVY contributed to a 6% revenue increase in 2023.
The company is expanding its presence in neuroscience, immunology, and immuno-oncology through strategic collaborations and new product launches.
Teva has also strengthened its position through acquisitions, notably acquiring PL Developments’ U.S. store-brand portfolio, bolstering its over-the-counter drug offerings.
This strategic diversification aligns with Teva’s goal to enhance market presence and drive long-term growth in the pharmaceutical industry, supported by investments in advanced technologies and partnerships aimed at accelerating mRNA-based treatments.
Geographical Presence
Teva Pharmaceuticals maintains a robust global presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East/Africa.
In North America, it operates from Pennsylvania, with extensive manufacturing and distribution capabilities serving the U.S. and Canada.
In Europe, Teva has established significant operations in Germany, the UK, France, and Spain, adhering to EMA standards.
The company also focuses on key Asia-Pacific markets like Japan and Australia, leveraging partnerships for growth.
In Latin America, Teva operates in Brazil, Mexico, and other countries, while in the Middle East/Africa, it serves markets such as Israel and South Africa through localized strategies.
This expansive footprint supports Teva’s global distribution network, ensuring wide access to its diverse portfolio of generic and specialty pharmaceuticals.
Recent Developments
- In May 2024, Teva Pharmaceuticals received approval from the US FDA for AUSTEDO XR tablets.
- In April 2024, Teva Pharmaceuticals partnered with Launch Therapeutics Inc. and Abingworth to expedite clinical research for Teva’s ICS-SABA (TEV-248).
Roche
Company Overview
| Establishment Year | 1896 |
| Headquarter | Basel, Switzerland |
| Key Management | Thomas Schinecker (CEO) |
| Revenue (US$ Bn) | $ 65.4 Billion (2022) |
| Headcount | ~ 122,000 (2022) |
| Website | http://www.roche.com/ |
About Roche
Roche is expanding its presence in mRNA technology through strategic partnerships and innovative projects.
Recently, the company signed a significant agreement with Remix Therapeutics, involving a substantial upfront payment and potential milestone payments totaling up to $1 billion, aimed at developing small molecules that target RNA processing for treating diseases.
Roche is also advancing its mRNA-based cancer vaccine, autogene cevumeran, in collaboration with BioNTech, with promising early-stage trial results in pancreatic cancer.
Emphasizing quality and innovation, Roche maintains robust manufacturing capabilities for mRNA reagents to ensure high standards in therapeutic production.
These efforts underscore Roche’s strategic commitment to leveraging mRNA advancements to address diverse medical needs, reinforcing its leadership in the biopharmaceutical field.
Geographical Presence
F. Hoffmann-La Roche AG, headquartered in Basel, Switzerland, boasts a global footprint spanning key regions worldwide.
In Europe, it operates major research facilities in Switzerland, Germany, the UK, and several other EU countries.
Across North America, Roche maintains significant operations in the US, including Genentech in South San Francisco, and serves the Canadian market.
In Asia-Pacific, it has established a strong presence in Japan, China, and Australia while also maintaining strategic bases in Latin America, notably Brazil and Mexico.
In the Middle East and Africa, Roche operates in South Africa and the UAE, supporting its comprehensive healthcare solutions globally through extensive R&D, manufacturing, and commercial operations.
Recent Developments
- In June 2024, Roche Digital Pathology Dx received approval from the US Food and Drug Administration.
- In August 2021, Roche’s FDA approval of the VENTANA MMR RxDx Panel highlighted its commitment to personalized healthcare through precise patient identification for tailored therapies.
Pfizer
Company Overview
| Establishment Year | 1849 |
| Headquarter | New York City, U.S. |
| Key Management | Albert Bourla (CEO) |
| Revenue (US$ Bn) | $ 58.5 Billion (2023) |
| Headcount | ~ 88,000 (2023) |
| Website | http://pfizer.com/ |
About Pfizer
Pfizer Inc. is making significant advances in mRNA technology, partnering with BioNTech to develop next-generation COVID-19 vaccines that aim to boost T-cell responses and provide extended protection.
They’ve also begun Phase 1/2 trials for an mRNA-based shingles vaccine and have shown promising results for a combination vaccine targeting COVID-19 and influenza.
In a notable collaboration with Beam Therapeutics, valued at up to $1.35 billion, Pfizer is focusing on developing in vivo base editing programs for rare diseases.
Additionally, Pfizer has secured a manufacturing reservation agreement with the European Commission to enhance preparedness for future pandemics, demonstrating their ongoing commitment to innovative mRNA treatments and vaccines.
Geographical Presence
Pfizer Inc., headquartered in New York City, maintains a robust global presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East/Africa.
In North America, it dominates with a substantial market share in the US and Canada. Across Europe, Pfizer operates in key markets like the UK, Germany, France, and Italy, supported by established distribution channels and research facilities.
In Asia-Pacific, it focuses on expanding healthcare access in countries such as China, Japan, India, and Australia.
In Latin America, Pfizer addresses health needs in Brazil, Mexico, and Argentina while also engaging in diverse markets across the Middle East and Africa.
Globally, Pfizer’s network includes research centers, manufacturing sites, and commercial offices, facilitating broad market reach and strategic flexibility.
Recent Development
- In October 2023, Pfizer reported favorable initial findings from a Phase 1/2 trial (NCT05596734) assessing the safety, tolerability, and immune response of mRNA combination vaccines targeting influenza and COVID-19 in healthy adults aged 18-64 years.
- In February 2023, Pfizer initiated a Phase 1/2 trial to assess the safety, tolerability, and immune response of their mRNA vaccine candidates against shingles caused by the varicella-zoster virus (VZV), a condition impacting millions annually worldwide.
Qiagen
Company Overview
| Establishment Year | 1984 |
| Headquarter | Venlo, Netherlands |
| Key Management | Thierry Bernard (CEO) |
| Revenue (US$ Bn) | $ 1.9 Billion (2023) |
| Headcount | ~ 5,967 (2023) |
| Website | http://qiagen.com/ |
About Qiagen
Qiagen N.V. has been actively bolstering its position in the mRNA sector with a focus on advancing molecular testing and sample technologies.
Recently, Qiagen obtained FDA clearance for its NeuMoDx CT/NG Assay, enhancing the detection of sexually transmitted infections on its NeuMoDx 96 and 288 systems.
This aligns with their strategy to expand their molecular testing portfolio. Qiagen has also launched an AI-driven biomedical knowledge base to accelerate drug discovery and research.
The company’s sustainability efforts, including achieving My Green Lab Platinum certification for eco-friendly QIAwave products, have garnered recognition.
Financially, Qiagen has announced a significant return of approximately $300 million to shareholders through a synthetic share repurchase, underscoring confidence in its growth prospects.
Geographical Presence
Qiagen NV, headquartered in the Netherlands, operates globally with a robust presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East/Africa.
In North America, it maintains offices, distribution centers, and research facilities, focusing on molecular diagnostics and life sciences solutions.
Throughout Europe, including Germany, France, the UK, and Switzerland, Qiagen has established key hubs for both commercial activities and research.
In the Asia-Pacific region, it serves markets like China, Japan, India, and Australia with offices and distribution centers, supporting regional growth.
In Latin America, including Brazil and Mexico, Qiagen addresses healthcare and research needs. Additionally, it has a strategic presence in select Middle Eastern and African countries, ensuring comprehensive global coverage in molecular biology and diagnostics.
Recent Developments
- In June 2024, QIAGEN unveiled the QIAstat-Dx Gastrointestinal Panel 2 in the US.
- In January 2024, QIAGEN announced a plan for a synthetic share repurchase, intending to return around $300 million to shareholders through a mix of direct capital repayment and a reverse stock split.
GE-Healthcare
Company Overview
| Establishment Year | 1994 |
| Headquarter | Chicago, Illinois, U.S. |
| Key Management | Peter Arduini (CEO) |
| Revenue (US$ Bn) | $ 19.5 Billion (2023) |
| Headcount | ~ 51,000 (2023) |
| Website | http://gehealthcare.com/ |
About GE Healthcare
GE Healthcare has actively pursued advancements in mRNA technology to enhance precision healthcare, which has been highlighted by strategic moves such as acquiring IMACTIS to bolster its interventional guidance capabilities.
Innovations like the Vscan Air SL, a wireless handheld ultrasound device, and expanded AI-driven digital solutions underscore its commitment to improving patient care.
In 2023, the company achieved substantial growth with $19.6 billion in revenue and invested $1 billion in R&D, emphasizing its dedication to leveraging new technologies for better healthcare outcomes and operational efficiency.
Geographical Presence
GE Healthcare, a subsidiary of General Electric, maintains a global presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East/Africa regions.
It offers a wide array of healthcare solutions, including medical imaging systems like MRI and CT scanners, healthcare IT solutions, and bioprocessing technologies.
GE Healthcare’s strategic focus on innovation and partnerships underscores its commitment to enhancing healthcare delivery and patient outcomes worldwide.
The company leverages its extensive geographical reach to cater to diverse healthcare needs while advancing medical technology and diagnostic capabilities globally.
Recent Developments
- In May 2024, GE Healthcare collaborated with Medis Medical Imaging to improve diagnostic precision and treatment of coronary artery disease.
- In February 2024, GE Healthcare partnered with Biofourmis to extend care beyond hospitals through safe, effective, and accessible home-based services, enhancing care continuity.
Discuss Your Needs With Our Analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
